Submit Deal

JUNO THERAPEUTICS INC

Summary

Juno Therapeutics operates as a clinical-stage biotechnology company. The Company focuses on developing immunotherapies for cancer and other research services. Juno Therapeutics serves the healthcare sector in the United States.

Deals Overview

Total Deals3

Valued Deals3

Total Value£ 6.09 B

Avg. Deal Size£ 2.03 B

Market Context

Senior Management

Hans Bishop
President and CEO
Steven D. Harr
CFO
Howard H. Pien
Chairman

Sort

22 Jan 2018|United States|Biotechnology

Target: JUNO THERAPEUTICS INC

Bidder: CELGENE CORPORATION

9 Service Providers

4 Target | 5 Bidder

60 Dealmakers

22 Target | 38 Bidder

£ 5.86 B

Value

11 May 2015|Germany|Biotechnology

Target: STAGE CELL THERAPEUTICS GMBH

Bidder: JUNO THERAPEUTICS INC

1 Service Providers

1 Bidder

2 Dealmakers

2 Bidder

£ 152 M

Value

09 Jun 2020|China|Biotechnology

Target: JW THERAPEUTICS

Bidder: CPE CAPITAL

12 Service Providers

1 Target | 11 Bidder

13 Dealmakers

1 Target | 12 Bidder

£ 78 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy